FDA Proposes Excluding Novo Nordisk and Eli Lilly Weight Loss Drugs from Bulk Compounding List
The FDA has proposed excluding the active ingredients in Novo Nordisk and Eli Lilly's obesity and diabetes medications from the list of drugs that can be compounded in bulk. This move is seen as favorable for the companies, as it would limit the production of cheaper alternatives unless the drugs are on the FDA's drug shortage list. The proposal targets semaglutide and tirzepatide, key ingredients in blockbuster drugs like Wegovy, Ozempic, Zepbound, and Mounjaro.
Topics: drug compounding Eli Lilly FDA Novo Nordisk regulatory proposal semaglutide tirzepatide